ENTITY
Ascletis Pharma Inc

Ascletis Pharma Inc (1672 HK)

81
Analysis
Health Care • China
Ascletis Pharma Inc. operates as a biotechnology company. The Company develops and discovers anti-viral drugs to address unmet medical needs in anti-viral, cancer, and fatty liver disease. Ascletis Pharma offers its services worldwide.
more
bullish•Meituan
•08 Sep 2018 13:18

ECM Weekly (8 September 2018) - Qutoutiao, Viomi, 111 Inc., Meituan, Haidilao

Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...

Share
bearish•Meituan
•03 Sep 2018 06:48

Last Week in GER Research: Meituan-Dianping, Nio, Gangfeng Lithium, Pinduoduo and 111 Inc

Below is a recap of the key IPO and fundamental research produced by the Global Equity Research team. This week we highlight a more palatable...

Logo
433 Views
Share
bearish•Hua Medicine Ltd
•03 Sep 2018 06:28

Hua Medicine IPO Preview: Suffering from the Ascletis Over-Valuation Syndrome

Hua Medicine Ltd (2552 HK) which specialises in developing drugs to treat Type 2 diabetes, is the third pre-profit biotech firm to IPO in Hong Kong...

Logo
908 Views
Share
bearish•Hua Medicine Ltd
•30 Aug 2018 14:31

Hua Medicine (åŽé¢†åŒ»čÆ) IPO: Little Upside to Fair Value

Hua Medicine launched theĀ institutional book building today and intends to raise USD 111 to USD 124 million, with an implied market capitalization...

Logo
583 Views
Share
•27 Aug 2018 06:05

Last Week in GER Research: Haidilao, Xiaomi, Ping An, 111, Qutoutiao, Nio and Tesla

Below is a recap of the key IPO and fundamental research produced by the Global Equity Research team. This week we highlight a differentiated...

Logo
459 Views
Share
x